Thunderbolt

Search documents
Disney's 'Elio' Posts Worst Pixar Opening: Here's Why Media Giant Likely Isn't Worried
Benzinga· 2025-06-23 16:26
The Pixar unit of Walt Disney Co DIS has been responsible for massive box office hits like the Toy Story, Finding Nemo, The Incredibles, Cars and Monsters Inc. franchises. The latest Pixar film is breaking records, but not in a good way.What Happened: New Disney film "Elio" from Pixar struggled in its box office debut, ranking third behind "28 Years Later" and the live-action family-friendly, "How to Train Your Dragon.""Elio" grossed $21 million domestically during its opening weekend, which is the worst op ...
USB 太多太乱?看这一篇就够了
半导体行业观察· 2025-06-07 02:08
公众号记得加星标⭐️,第一时间看推送不会错过。 来源:内容来自 slashgear 。 USB 于 1990 年代末被引入,作为一种通用的接口,替代了当时设备上常见的各种端口和连接方式, 彻底改变了我们使用电脑的方式。如今,USB 已成为连接外设和外部存储设备到 PC、笔记本或智能 手机的标准接口。曾经的串口和 PS/2 端口已经一去不复返,取而代之的是一种相对简单明了的标 准。 不过,也算是吧。你看,虽然 USB 确实比过去主板上需要面对的两三种不同类型端口方便得多,但 这个协议并不像我们想象的那样单一。尽管像 USB Mini B 和 Micro USB 这样的连接器已经在新型 消费设备中逐渐消失,但如今普遍存在的 USB-A 和 USB-C 接口,依然支持着一系列令人眼花缭乱 的速度和标准。 幸运的是,USB 实施者论坛(USB-IF)设计了一套图标,帮助用户快速识别某个 USB 端口所支持 的协议类型及其性能表现。遗憾的是,并不是所有设备或组件都会使用这些标志,因为它们需要付费 认证。尽管如此,这些仍是截至 2025 年官方 USB-IF 认证的 USB 端口图标,我们接下来将重点介 绍这些标志。值得 ...
Penumbra (PEN) 2025 Conference Transcript
2025-06-04 14:57
Penumbra (PEN) 2025 Conference June 04, 2025 09:55 AM ET Speaker0 Okay. So we're ready to kick off. This is the fireside chat with Penumbra. My name is Mike Sarcone. I'm one of the analysts on the US medical supplies and devices team. And with us from the company today, we have Adam El Seltzer. He's co founder, president, chairman, and CEO. We've also got Jason Mills, director of strategy. And Cecilia Furlong, who is a director of business Development, is also here with us. So team, thank you for joining us ...
Penumbra (PEN) FY Conference Transcript
2025-06-03 20:00
Summary of Penumbra (PEN) FY Conference Call - June 03, 2025 Company Overview - **Company**: Penumbra, a medical technology company based in Alameda, California, specializing in thrombectomy and embolization products [5][6] - **Employees**: Over 4,500 [6] - **Market Position**: Penumbra is recognized as a leading player in the VTE (Venous Thromboembolism) market, with significant growth potential [2][3] Industry Insights - **VTE Market Growth**: The VTE market is experiencing a shift towards mechanical thrombectomy products, with a projected market growth of 20% in 2025 and beyond [3][48] - **Competitor Challenges**: One of Penumbra's largest competitors is facing integration issues, presenting an opportunity for Penumbra to capture market share [3] - **Clinical Data Impact**: Upcoming clinical data is expected to influence societal guidelines and increase the adoption of mechanical thrombectomy [3] Product Innovations - **CAPT Platform**: A new CAPT platform for neuro is anticipated to drive growth, similar to previous innovations in VTE [3] - **Thrombectomy Technology**: Penumbra's current technology, CABT (Computer Assisted Vacuum Thrombectomy), enhances the effectiveness of clot removal [14][15] - **Device Efficiency**: Recent advancements have reduced device time for clot removal to as low as two minutes, significantly improving patient outcomes [21][22][26] Financial Performance - **Revenue Growth**: Penumbra has reported over 40% growth in VTE for several quarters, with expectations to maintain this momentum [46][48] - **China Market Impact**: Revenue from China has declined due to tariffs and economic conditions, which could affect overall growth projections [44] Strategic Focus - **Four-Pronged Strategy**: The company aims to focus on innovation, commercial team investment, market access, and margin expansion to drive future growth [33][35] - **Market Access Initiatives**: Penumbra is working with hospitals to demonstrate the clinical and financial benefits of their products, aiming to increase treatment rates for DVT and PE [38][39] Key Takeaways - **Patient Impact**: Penumbra's products are designed to significantly improve patient outcomes, with a focus on treating a larger percentage of potential cases [52][53] - **Long-Term Growth Potential**: The combination of innovative products, market access strategies, and a growing VTE market positions Penumbra for sustained growth in the coming years [3][48][53]
Minisforum to Unveil Unparalleled AI New Products at COMPUTEX TAIPEI 2025
Globenewswire· 2025-05-20 13:28
Group 1 - Minisforum will participate in COMPUTEX TAIPEI 2025 from May 20th to May 23rd, showcasing its latest AI mini PCs and next-generation computing solutions [1][8] - The company will display a variety of new mini PCs optimized for gaming, creative work, and business applications, featuring the latest AMD Ryzen 9000 series and Intel Core Ultra processors [2] - A hands-on experience area will be available for visitors to explore the AI mini PC, Minisforum AI X1 Pro, along with various AI software solutions in collaboration with Wondershare [3] Group 2 - Minisforum's engineers and product experts will provide technical advice and customization suggestions at the event [4] - The exhibition will take place at Nangang Exhibition Hall 1, Taipei, with booth M1334 [5] - The company aims to present the possibilities of next-generation computing with higher performance and smaller form factors [5]
Penumbra (PEN) 2025 Conference Transcript
2025-05-13 23:00
Summary of Penumbra (PEN) 2025 Conference Call Company Overview - **Company**: Penumbra, Inc. (PEN) - **Market Cap**: Increased from $1 billion to approximately $11.12 billion over the past decade [3][4] Core Industry Insights - **Industry**: Medical Devices, specifically focusing on thrombectomy and stroke treatment - **Market Dynamics**: The competitive landscape has evolved, with Penumbra transitioning from competing against other companies to focusing on internal innovation [5][6][15] Key Points and Arguments 1. **Innovation as a Growth Driver**: Penumbra attributes its success to continuous innovation and improvement of its products, particularly in thrombectomy technology [4][5] 2. **Digital Transformation**: The company is entering a digital age, enhancing its product capabilities through software improvements rather than solely hardware changes [6][10] 3. **Market Leadership**: Penumbra remains a dominant player in the aspiration thrombectomy market, despite increased competition from private companies [15][16] 4. **Challenges in Stroke Treatment**: Structural issues in the healthcare system hinder patient access to treatment, impacting growth in the stroke market [17][18] 5. **Regulatory Process**: The company is currently in the FDA review process for its Thunderbolt product, with no significant updates on the timeline for approval [22][23] 6. **Market Access Strategy**: Penumbra is working on demonstrating the clinical and economic benefits of its products to hospitals, aiming to change treatment protocols [50][51][52] 7. **Growth in VTE Market**: The company has seen a 42% growth rate in the US venous thromboembolism (USVT) market, driven by peer recommendations among physicians [43][48] 8. **China Market Impact**: Revenue from China has significantly decreased, impacting overall guidance, but the company remains optimistic about future opportunities [65][67] Additional Important Insights - **Quality of Life Measures**: The company emphasizes the importance of quality of life in its clinical trials, particularly for patients undergoing treatment for intermediate pulmonary embolism [59][61] - **Product Launches**: Excitement around new product launches, such as Ruby XL, indicates ongoing innovation and market engagement [68][69] - **Economic Considerations**: The economic benefits of using Penumbra's products over traditional treatments are highlighted, suggesting a potential shift in hospital protocols [52][53] This summary encapsulates the key insights and strategic directions discussed during the conference call, reflecting Penumbra's focus on innovation, market dynamics, and growth opportunities in the medical device industry.
3 Reasons Why Disney Stock May Be a Smart Buy After Q2 Earnings Beat
ZACKS· 2025-05-13 13:26
Disney (DIS) delivered impressive second-quarter fiscal 2025 results that exceeded the Zacks Consensus Estimate for both earnings and revenues, demonstrating strong momentum across its business segments. (Read More: Disney Q2 Earnings Surpass Estimates, Revenues Increase Y/Y)With shares trading below their historical premium despite the company's improved financial outlook, Disney stock appears increasingly attractive for investors looking for both growth and stability.Impressive Financial Performance Shows ...
Disney Stock Is Finally Back in Action. Will new Tariffs Derail It?
The Motley Fool· 2025-05-11 08:12
Core Viewpoint - Disney is showing signs of recovery and growth across all segments, with strong financial results for the second quarter of fiscal 2025, indicating a positive outlook for the company [1][6][11]. Financial Performance - Total revenue for the second quarter increased by 7% year-over-year to $23.6 billion, surpassing Wall Street expectations of $23.14 billion [6]. - All segments reported profitability, with entertainment operating income rising by 61%, and direct-to-consumer operating income reaching $336 million, up from $47 million the previous year [7]. - Disney+ added 1.4 million subscribers, while the Disney+ and Hulu bundle gained 2.5 million subscribers [7]. - Earnings per share (EPS) were reported at $1.45, exceeding the consensus target of $1.20 [7]. Segment Performance - The entertainment segment grew by 9%, parks by 6%, and sports by 5% [6]. - Disney studios had the top three highest-grossing films last year and a strong slate of 10 movies expected for release this year, including the next installment in the Avatar series [9]. Future Outlook - Management expressed confidence in continued profit increases across all segments and overall company earnings for the remainder of the year [11]. - Disney is on track to launch its ESPN streaming service later this year and plans to open a new theme park in Abu Dhabi, which will be a low-risk project as it will not require additional capital investment [10]. External Factors - The recent announcement of tariffs on foreign-made films by the Trump administration has raised concerns, but Disney management remains confident in their near-term outlook and profitability despite the uncertainty surrounding the tariffs [12][13]. - Following the tariff announcement, Disney's stock initially fell but rebounded after the earnings report, showing a 23% increase over the past month [14].
Tariff Talk Returns to Sink Markets; Plus Q1 Earnings
ZACKS· 2025-05-06 23:05
Market Performance - Market indexes experienced a decline, with the Dow dropping 389 points (-0.95%), S&P 500 down 43 points (-0.77%), Nasdaq falling 154 points (-0.87%), and Russell 2000 losing 21 points (-1.05%) [1] Company Earnings Reports - Advanced Micro Devices (AMD) reported earnings of 96 cents per share, beating estimates by 3 cents, with revenues of $7.44 billion surpassing the projected $7.12 billion. Forward revenue guidance was raised to $7.4 billion [3] - Wynn Resorts (WYNN) reported earnings of $1.07 per share, missing the estimate of $1.22, and revenues of $1.7 billion, slightly below the $1.73 billion estimate. The company announced a share buyback program, but faces challenges due to tariff concerns affecting its domestic locations [4] - Rivian Automotive (RIVN) posted a narrower loss of 41 cents per share compared to the expected 80 cents, with revenues of $1.24 billion exceeding the $1.02 billion estimate. The gross profit of $206 million positions the company favorably with Volkswagen, which has invested in Rivian [5] Upcoming Earnings Expectations - The Walt Disney Co. (DIS) is expected to report fiscal Q2 earnings with a projected decline of 2.48% in earnings growth, while top-line growth is anticipated at 4.77%. The Parks division and the film "Thunderbolts" are expected to attract significant interest [6] Federal Reserve Meeting - The Federal Open Market Committee (FOMC) meeting is concluding, with no expected change in interest rates. Fed Chair Jerome Powell will address questions regarding the timeline for potential rate reductions and his position before the end of his term in 2026 [7]
Disney and Marvel's 'Thunderbolts*' snares $76 million domestic opening
CNBC· 2025-05-04 15:45
Core Insights - The summer box office has been revitalized by Disney and Marvel's "Thunderbolts," which earned an estimated $76 million domestically during its opening weekend, marking the third highest debut of 2025 [1] - The film's global earnings, including international ticket sales, reached approximately $162.1 million [1] - Analysts suggest that May is on track to become one of the best months on record for box office performance [1] Group 1 - Last year's summer box office faced challenges, with Universal's "The Fall Guy" only generating $28 million in its opening weekend, marking the first year since 2009 without a Marvel film to kick off the season [2] - Marvel films have struggled to match the success of "Avengers: Endgame" from 2019, with mixed performances in recent releases such as "The Marvels" and "Captain America: Brave New World," while "Deadpool & Wolverine" exceeded expectations [3][4] - "Thunderbolts" has received positive reviews, holding an 88% "Fresh" rating on Rotten Tomatoes from 257 reviews and a 94% audience rating, indicating strong word-of-mouth support [5] Group 2 - The opening weekend performance of "Thunderbolts" is seen as a promising start, with expectations for long-term success similar to other recent films like "A Minecraft Movie" and "Sinners," which have shown consistent audience interest [6]